Global Generic Oncology Sterile Injectable Market By Product Type (Chemotherapy, Monoclonal Antibodies, Cytokines, and Peptide Hormones), By Disease Indication (Ovarian Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region - Trends and Forecast till 2015

Generic Oncology Sterile Injectable Market Insights

Generic oncology sterile injectables are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectables have to adhere to regulations by the Food and Drug Administration (FDA) for the process of development of these injectables, which are equivalent to that for branded counterparts. These generic oncology sterile injectables are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus. These injectables are available at low prices, and therefore, are widely preferred over branded. Furthermore, R&D for generic drugs requires less capital, which increases competition to enter into generic oncology sterile injectable market as soon as the patent for branded injectables expires. However, the emergence of biosimilars has increased in past few years. After Europe, the number of biosimilars approved is increasing in the U.S. market. This is expected to contribute largely towards the generic oncology sterile injectable market growth during the forecast period.

The key players in generic oncology sterile injectable market includes, Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Rising number of cancer cases is expected to fuel demand for treatment drugs and injectables. According to the World Cancer Research Fund International (WCRFI), around 14.1 million cancer cases were reported worldwide, in 2012. As per WCRFI, it is projected that by 2035, around 24 million cancer cases are expected to increase. This is expected to drive growth of the generic oncology sterile injectable market.

The global generic oncology sterile injectable market was valued at US$ 8.9 Billion in 2016 and is expected to exhibit a CAGR of 11.4% over the forecast period (2017–2025).

Figure 1. Global Generic Oncology Sterile Injectable Market Value (US$ Mn), By Region – 2016

generic oncology sterile injectable market

Source: Coherent Market Insights (2017)

Expansion of manufacturing facilities and mergers between key players to develop strong pipeline product is expected to propel the generic oncology sterile injectable market growth

Manufacturers in the market are focusing on collaboration and expansion of manufacturing facilities to tap into emerging markets. For instance, In July 2017, India-based Alembic Pharmaceuticals established an oncology manufacturing facility for injectables and lyophilized products in Gujarat. The manufacturing site has a capacity for 60 million tablets and capsules, approximately 20 million vials capacity for liquid injectables and lyophilized product. This new manufacturing facility will develop oncology injectables and lyophilized products for sales in international markets of the U.S., Middle East, North Africa, South Africa, and Australia. Furthermore, in December 2016 the global leader, Baxter International acquired India-based Claris Injectables for expanding its generic injectables product portfolio such as in oncology. This acquisition is expected to strengthen Baxter’s sales in hospitals in order to gain a leading position in generic injectables market. Also, in August 2017, Hikma Pharmaceuticals increased its additional manufacturing capacity by 70 million units exclusively for oncology injectables, which brings up its total to 550 million units. Therefore, this expansion will help Hikma to maintain its position in the market.

In October 2014, Sagent Pharmaceuticals, Inc., a leader in injectables, acquired Omega Laboratories Limited. This acquisition is expected to aid in creating a robust product portfolio in generic injectables and expand Sagent’s global presence. Omega has a strong pipeline consisting of 26 generic injectables, planned to be launched between 2014 and 2019 and this is expected to aid Sagent.

In October 2017, Eli Lilly & Company received intellectual property rights for the vitamin regimen for Alimta (pemetrexed for injection) by the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO). These rights are expected to aid Eli Lilly & Company for development of next generation medicines.

Generic oncology sterile injectables are used in treatment of various types of cancers such as ovarian, breast, and lung. These drugs are relatively cheaper than branded counterparts. This is owing presence of same active ingredients, although its inactive contents are different. Cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of a few cancer drugs by 86% in March 2017. Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry is expected to fuel growth of the generic oncology sterile injectables during the forecast period. Also, the emergence of biosimilars has also impacted growth of generics drugs. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars had a major share in Europe since 2013 and in the U.S. since 2015 and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Market Dynamics

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancers were reported in the U.S. Manufacturers are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following U.S. Food and Drug administration approval in the U.S. market.  Clofarabine is a generic version of Genzyme's Clolar, which is used for treatment of refractory acute lymphoblastic leukemia for patients aged 1 year to 21 years.

Key features of the study:

  • This report provides in-depth analysis of the generic oncology sterile injectables market and its product type, market size (US$ Million), and Cumulative Annual Growth Rate (CAGR %) for the forecast period: 2017 – 2025, considering 2016as the base year.
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players.
  • It profiles leading players in the generic oncology sterile injectables market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans.
  • Key companies covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launches, distribution channel, market expansion, and marketing tactics.
  • The generic oncology sterile injectables market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for generic oncology sterile injectables market, research and consulting firms, new entrants and financial analysts.
  • Various strategy matrices used in analyzing the generic oncology sterile injectables market would provide stakeholders vital inputs to make strategic decisions accordingly.

Detailed Segmentation:

  • Global Generic Oncology Sterile Injectable Market, By Product Type:
    • Chemotherapy
      • Alkylating agents
      • Antimetabolites
      • Plant Alkaloids
      • Antitumor Antibiotics
      • Others
    • Monoclonal Antibodies
    • Cytokines
    • Peptide Hormones
  • Global Generic Oncology Sterile Injectable Market, By Disease Indication:
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Others
  • Global Generic Oncology Sterile Injectable Market, By Distribution Channel :
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Generic Oncology Sterile Injectable Market, By Regions :
    • North America
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Rest of Latin America
    • Europe
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Eli Lilly & Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
      • Future Plans
    • Biocon Ltd.
    • Baxter International Inc.
    • Hikma Pharmaceuticals PLC
    • Mylan N.V.
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.

“*” marked represents similar segmentation in other categories in the respective section

Table of Contents

  1. Research Objective and assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Regulatory Scenario
    • Industry Trend
    • Merger and Acquisitions
    • New Product Approvals/Launch
    • Promotion and Marketing Initiatives
  4. Global Generic Oncology Sterile Injectable Market, By Product Type, 2017 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
        • Alkylating agents
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
        • Antimetabolites
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
        • Plant Alkaloids
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
        • Antitumor Antibiotics
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Cytokines
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Peptide Hormones
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  5. Global Generic Oncology Sterile Injectable Market, By Disease Indication, 2017 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Pancreatic Cancer
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  6. Global Generic Oncology Sterile Injectable Market, By Distribution Channel, 2017 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, 2017 and 2025 (%)
      • Y-O-Y Growth Analysis, 2015 - 2025
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-O-Y Growth, 2015 - 2025, (US$ Million)
  7. Global Generic Oncology Sterile Injectable Market, By Regions, 2017 - 2025 (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2017 and 2025 (%)
      • Y-o-Y Growth Analysis, For Regions, 2015 – 2025
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • Brazil
        • Mexico
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of APAC
    • Middle East
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2015 - 2025 (US$ Mn)
      • Market Size and Forecast, By Country, 2015 - 2025 (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Eli Lilly & Company
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Biocon Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Sandoz International GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Developments/Updates
        • Future Plans
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 25 figures on "Generic Oncology Sterile Injectable Market” - Global forecast to 2025”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.